News

2,3-Dimethyl-2H-indazol-6-amine (CAS# 444731-72-0), also known as 6-amino-2,3-dimethyl-2H-indazole, 2,3-dimethyl-6-amino-2H-indazole, 2,3-dimethylindazol-6-amine, or Pazopanib Related Compound 5, is a regioselectively methylated indazole derivative with the molecular formula C₉H₁₁N₃ and a molecular weight of 161.20 g/mol. Its molecular structure features an indazole bicyclic core bearing methyl groups at both the N2 and C3 positions, with a primary amino group at the C6 position. This specific substitution pattern—N2-methylation that fixes the indazole in the 2H-tautomer form and C3-methylation that provides steric and electronic modulation—is synthetically challenging to achieve regioselectively but essential for the biological activity of the final drug molecule.

As a solid crystalline powder with a boiling point of 366.9±22.0°C (predicted), a density of 1.23±0.1 g/cm³, and a pKa of 4.20±0.30, the compound exhibits a dark brown to very dark orange color and is soluble in DMSO and methanol (slightly soluble). It should be stored at 2–8°C under an inert atmosphere, protected from light and moisture. The compound is typically supplied at ≥97% purity (HPLC) with ≥99% grades available for demanding pharmaceutical applications.

2,3-Dimethyl-2H-indazol-6-amine is the definitive 2H-indazole building block and non-negotiable intermediate for the synthesis of Pazopanib (Votrient®)—a marketed multi-target tyrosine kinase inhibitor (TKI) approved for the treatment of renal cell carcinoma (RCC) and soft tissue sarcoma (STS). Unlike conventional kinase inhibitors that bind the ATP hinge region, Pazopanib’s 2,3-dimethyl-2H-indazole core sits deep in the hydrophobic pocket behind the gatekeeper residue, while the hinge interaction is handled by the 2-aminopyrimidine moiety attached to the C6-amine. This unique binding mode (Type II, DFG-out conformation) confers high selectivity for the angiokinase spectrum—VEGFR1/2/3, PDGFR, and c-Kit—making this compound a strategically critical building block in precision oncology. Based on its chemical characteristics and industrial significance, this article systematically analyzes the key properties, core application areas, global market structure, regulatory landscape, and future outlook of this strategically important heterocyclic building block.

Key Properties and Reactivity Profile

2,3-Dimethyl-2H-indazol-6-amine (CAS# 444731-72-0) is a regioselectively methylated indazole whose value derives from the precise positioning of its three substituents.

Key physicochemical parameters include:

Molecular Formula: C₉H₁₁N₃
Molecular Weight: 161.20 g/mol
CAS Number: 444731-72-0
Synonyms: 6-Amino-2,3-dimethyl-2H-indazole; 2,3-Dimethyl-6-amino-2H-indazole; 2,3-Dimethylindazol-6-amine; Pazopanib Related Compound 5
MDL Number: MFCD09258896
Appearance: Solid; dark brown to very dark orange
Purity: ≥97% (HPLC); ≥99% available
Boiling Point: 366.9±22.0°C at 760 mmHg (predicted)
Density: 1.23±0.1 g/cm³ (predicted)
pKa: 4.20±0.30 (predicted)
Solubility: DMSO (slightly), methanol (slightly)
Storage: 2–8°C, protect from light and moisture, inert atmosphere
GHS Classification: Warning; H302 (Harmful if swallowed)
REACH Registration: Active
HS Code: 2922390090

The compound’s reactivity is defined by its C6-amine group, which serves as the primary reactive site for nucleophilic coupling with pyrimidines—specifically the coupling with 2,4-dichloropyrimidine to form the key intermediate N-(2-chloropyrimidin-4-yl)-2,3-dimethyl-2H-indazol-6-amine (CAS 444731-74-2). The C3-methyl group is chemically inert under standard coupling conditions, providing steric protection without interfering with the critical amination reaction. The N2-methylation is the defining structural feature—it fixes the indazole in the 2H-tautomer form, which is essential for Pazopanib’s biological activity. The synthetic challenge lies in achieving regioselective N2-methylation over the competing N1-methylation pathway, requiring careful control of reaction temperature (maintained at 60°C) and purification by crystallization to remove the undesired N1-isomer.

Core Application Fields and Demand

Market demand for 2,3-dimethyl-2H-indazol-6-amine (CAS# 444731-72-0) is concentrated in three primary sectors: pharmaceutical synthesis and Pazopanib manufacturing (approximately 55–60% of global consumption), pharmaceutical impurity reference standards and quality control (approximately 20–25%), and kinase inhibitor R&D and medicinal chemistry (approximately 15–20%). Its unique regioselective 2H-indazole structure and essential role in Pazopanib synthesis serve as the core drivers of sustained demand growth.

In pharmaceutical synthesis and Pazopanib manufacturing, 2,3-dimethyl-2H-indazol-6-amine is the essential intermediate in the synthesis of Pazopanib hydrochloride (Votrient®)—an oral angiogenesis inhibitor targeting VEGFR, PDGFR, and c-Kit, approved by the FDA in 2009 for advanced renal cell carcinoma and in 2012 for soft tissue sarcoma. The compound’s role in the Pazopanib synthetic route is non-negotiable: the free amine at C6 is coupled with 2,4-dichloropyrimidine to form N-(2-chloropyrimidin-4-yl)-2,3-dimethyl-2H-indazol-6-amine, which is subsequently reacted with 5-amino-2-methylbenzenesulfonamide in the presence of hydrochloric acid in isopropanol and ether to yield Pazopanib hydrochloride. In the Pazopanib synthetic route, the 2,3-dimethyl-2H-indazole core does not bind the kinase hinge region; instead, it sits deep in the hydrophobic pocket behind the gatekeeper residue, with the hinge interaction handled by the 2-aminopyrimidine moiety attached to the C6-amine. This unique binding mode (Type II, DFG-out) confers high selectivity for the angiokinase spectrum, making the 2,3-dimethyl-2H-indazole core essential for the drug’s biological activity. The compound’s structure-dependent reactivity—where the specific pattern of N2 versus N1 methylation determines the tautomeric form and ultimately the drug’s binding mode—makes regioselective synthesis a critical challenge that directly impacts downstream pharmaceutical efficacy.

In pharmaceutical impurity reference standards and quality control, 2,3-dimethyl-2H-indazol-6-amine serves as Pazopanib Impurity 7 (also designated as Pazopanib Related Compound 5), an essential reference standard for pharmaceutical quality control and analytical method validation. The compound is used as an ICH Q3A/Q3B-compliant reference standard, working standard, and pharmaceutical intermediate for supporting pharmaceutical companies worldwide with accurate and reliable impurity solutions for drug development. Its defined structure and high purity make it suitable for use in HPLC and LC-MS method development, validation, and quality control in the radiopharmaceutical and oncology drug manufacturing industry.

In kinase inhibitor R&D and medicinal chemistry, 2,3-dimethyl-2H-indazol-6-amine serves as a valuable building block for the synthesis of Pazopanib-inspired kinase inhibitor libraries and related 2H-indazole VEGFR inhibitors. The compound is specifically noted as the “non-negotiable standard” for medicinal chemistry teams synthesizing Pazopanib-inspired kinase inhibitor libraries, where the 2,3-dimethylated scaffold is mandatory for achieving the correct hydrophobic anchor binding mode. Researchers utilize this compound to construct focused libraries of 2H-indazole-based kinase inhibitors targeting the angiokinase spectrum, enabling structure-activity relationship (SAR) studies and the development of next-generation VEGFR/PDGFR inhibitors with improved selectivity and pharmacokinetic profiles. The compound also serves as a direct synthetic precursor to N,2,3-trimethyl-2H-indazol-6-amine (CAS 1376676-65-1), further expanding its utility in medicinal chemistry research.

Major Market Participants

The global supply system for 2,3-dimethyl-2H-indazol-6-amine (CAS# 444731-72-0) features a pattern of “specialized pharmaceutical intermediate manufacturers, multinational research chemical distributors, and Chinese producers serving distinct market segments.” As a specialized heterocyclic building block rather than a bulk commodity, the market is characterized by a moderate number of suppliers catering to pharmaceutical R&D, API manufacturing, and academic research. According to the Global Market Report of 2,3-Dimethyl-6-amino-2H-indazole (CAS 444731-72-0), comprehensive data is available globally and regionally covering Europe, Asia, North America, and Latin America, including manufacture methods, market situation, and distribution policy.

In the global research and high-purity segment, key international suppliers include Sigma-Aldrich (Merck), offering the compound at ≥97% purity under product code AMBH2D6F6CE0, with storage at 2–8°C under inert atmosphere and country of origin CN. AK Scientific (AKSci) offers the compound at 95% purity under product code J53669 with MDL number MFCD09258896. CymitQuimica offers the compound with packaging from 1 g (€26.00) to 100 g (€143.00). ChemScene offers the compound under catalog number CS-B0766 with 100 g packaging available. TargetMol offers the compound under catalog number BT13158 with pricing of ¥76 for 1 g, ¥81 for 5 g, ¥326 for 25 g, and ¥1,263 for 100 g. Bide Pharmatech offers the compound at 97% purity with batch quality inspection reports (NMR, HPLC, GC). Santa Cruz Biotechnology offers the compound for research applications. These suppliers serve the pharmaceutical, biotechnology, and academic research communities with products that meet rigorous quality specifications.

In the industrial and large-scale production segment, Chinese manufacturers have emerged as significant players in the global supply chain. XinChem is a reliable manufacturer and supplier of high-purity 2,3-dimethyl-2H-indazol-6-amine from China, offering the compound with stringent quality standards for use in Pazopanib synthesis, pharmaceutical impurity standards, and kinase inhibitor R&D. XinChem provides the compound as a solid crystalline powder with comprehensive quality documentation and flexible packaging options. The compound is classified as a pharmaceutical intermediate and is available for bulk supply. Chinese manufacturers offer the compound at various purity grades (typically 95–99%) and packaging options—from grams to multi-kilogram quantities—serving both domestic and export markets. Production scale capabilities include up to 200 kg quantities with packaging options of 5 kg, 25 kg, and 200 kg drums. Other Chinese suppliers include manufacturers concentrated in major chemical manufacturing regions including Hubei, Shanghai, and other industrial provinces, offering the compound at 99% purity with storage at 2–8°C and a shelf life of one year.

Regional Market Dynamics

The global 2,3-dimethyl-2H-indazol-6-amine market exhibits distinct regional characteristics, with production concentrated in Asia-Pacific (particularly China) and consumption distributed across North America, Europe, and the Asia-Pacific region, aligned with the pharmaceutical, oncology, and biotechnology industries in these regions. The compound’s market is driven by the continued growth of targeted cancer therapies, particularly angiokinase inhibitors for renal cell carcinoma and soft tissue sarcoma.

The Asia-Pacific region has emerged as a significant production hub for 2,3-dimethyl-2H-indazol-6-amine, with China hosting numerous manufacturers and suppliers including XinChem. The region’s competitive advantages include lower production costs, established chemical infrastructure, and proximity to rapidly growing pharmaceutical industries. Chinese suppliers offer the compound at various purity grades (typically 95–99%) and packaging options, serving both domestic and export markets. The growing pharmaceutical R&D and API manufacturing sectors in China, India, Japan, and South Korea continue to drive regional consumption growth. The compound is listed as a pharmaceutical intermediate with country of origin CN under Sigma-Aldrich’s product listings, reflecting China’s role as a key global supplier. With the global Pazopanib market experiencing steady growth driven by increasing cancer incidence and expanding access to targeted therapies, Chinese manufacturers are well-positioned to supply the growing demand for this critical intermediate.

North America remains a key market for high-purity and research-grade 2,3-dimethyl-2H-indazol-6-amine, driven by demand from the pharmaceutical industry, biotechnology companies, and academic research institutions. The United States hosts numerous research organizations, pharmaceutical companies, and contract research organizations that require high-quality heterocyclic building blocks for Pazopanib manufacturing and kinase inhibitor drug discovery. Sigma-Aldrich, AK Scientific, ChemScene, and TargetMol serve the North American market with extensive distribution networks. The region’s well-established regulatory framework, including FDA oversight of oncology drug manufacturing and ICH Q3A/Q3B impurity standards, supports demand for high-grade reference standards and pharmaceutical intermediates.

Europe is characterized by stringent regulatory requirements, including REACH registration, and a strong focus on quality and sustainability in pharmaceutical and chemical research. European pharmaceutical companies, oncology drug manufacturers, and research institutions demand high-purity heterocyclic building blocks with comprehensive documentation. CymitQuimica and other distributors serve the European market with in-stock availability. The region’s advanced oncology drug development infrastructure and strict ICH compliance requirements support steady demand for high-quality Pazopanib intermediates and impurity standards.

Japan represents a specialized market where 2,3-dimethyl-2H-indazol-6-amine is supplied by distributors for pharmaceutical research, oncology drug manufacturing, and fine chemical applications.

Regulatory and Safety Considerations

As a pharmaceutical intermediate and research chemical, 2,3-dimethyl-2H-indazol-6-amine (CAS# 444731-72-0) is subject to regulatory oversight in major global economies. Compliance with relevant regulations is essential for market access and trade.

GHS classification and handling: 2,3-Dimethyl-2H-indazol-6-amine is classified with the signal word ”Warning”. Hazard statements include H302 (Harmful if swallowed). Precautionary statements include P264 (Wash skin thoroughly after handling), P270 (Do not eat, drink or smoke when using this product), P301+P312 (IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell), P330 (Rinse mouth), and P501 (Dispose of contents/container to an approved waste disposal plant). The compound should be stored at 2–8°C under inert atmosphere, protected from light and moisture. Personal protective equipment including lab gloves, safety glasses, and a lab coat should be worn during handling, and operations should be conducted in a well-ventilated environment.

Storage and stability: The compound should be stored at 2–8°C, protected from light, under inert atmosphere (nitrogen or argon). It is recommended to keep the container tightly closed and protect from moisture. The compound is stable under recommended storage conditions but should be kept away from strong oxidizing agents.

Regulatory compliance: In the European Union, the compound must comply with REACH registration requirements for import and use. The compound has an active REACH registration status. Manufacturers and suppliers must provide comprehensive Safety Data Sheets (SDS) and maintain appropriate documentation. In the United States, 2,3-dimethyl-2H-indazol-6-amine is intended for research and development use only and is not intended for therapeutic, food, cosmetic, or consumer applications unless explicitly stated otherwise. For pharmaceutical intermediate applications, manufacturers must comply with relevant FDA regulations and quality standards, including ICH Q3A/Q3B requirements for impurity standards. The compound is not a controlled substance.

Transport information: 2,3-Dimethyl-2H-indazol-6-amine is not classified as hazardous material for DOT/IATA transport purposes. Proper packaging, labeling, and documentation are nevertheless required for international shipping. The HS code for the compound is 2922390090 (heterocyclic compounds with nitrogen hetero-atoms only). The compound is typically shipped at ambient temperature with appropriate protection from light and moisture.

Future Outlook

The market outlook for 2,3-dimethyl-2H-indazol-6-amine is positive, supported by several key growth drivers across its major application segments. While the compound remains a relatively specialized heterocyclic building block, its essential role as the definitive 2H-indazole intermediate for Pazopanib and its utility in kinase inhibitor R&D position it for steady growth in the coming years.

Key growth drivers include:

Expansion of the Pazopanib market and angiokinase inhibitor therapeutics: The continued global demand for Pazopanib (Votrient®)—a multi-target TKI approved for renal cell carcinoma and soft tissue sarcoma—drives demand for the key intermediate 2,3-dimethyl-2H-indazol-6-amine. Rising cancer incidence, expanding access to targeted therapies in developing countries, and the growth of the global oncology drug market support sustained demand for the compound. The compound’s unique binding mode—sitting in the hydrophobic pocket behind the gatekeeper residue—confers high selectivity that makes it essential for Pazopanib’s biological activity.
Growth in pharmaceutical impurity reference standards and quality control: The increasing stringency of pharmaceutical quality control requirements, particularly ICH Q3A/Q3B compliance for oncology drugs, drives demand for well-characterized impurity reference standards. 2,3-Dimethyl-2H-indazol-6-amine serves as Pazopanib Impurity 7, an essential reference standard for pharmaceutical quality control and analytical method validation.
Expansion of kinase inhibitor R&D and medicinal chemistry: The growing emphasis on kinase inhibitor discovery, particularly in oncology, drives demand for regioselective 2H-indazole building blocks for constructing Pazopanib-inspired kinase inhibitor libraries. The compound’s specific 2,3-dimethyl-2H-indazole scaffold is mandatory for achieving the correct hydrophobic anchor binding mode in angiokinase inhibitors.
Increasing focus on regioselective synthesis: The growing recognition of the critical role of N2 versus N1 methylation in determining the tautomeric form and biological activity of 2H-indazole derivatives drives demand for high-quality, regioselectively synthesized 2,3-dimethyl-2H-indazol-6-amine. The synthetic challenge of achieving regioselective N2-methylation over N1-methylation makes this compound a valuable building block for researchers developing novel kinase inhibitors.
Expansion of pharmaceutical R&D in Asia: The growth of pharmaceutical R&D and API manufacturing in China and India—driven by increasing investment in generic drug production and innovative drug discovery—supports demand for high-quality pharmaceutical intermediates and reference standards.

Challenges and considerations:

Regulatory compliance: Increasingly stringent pharmaceutical and chemical regulations may require ongoing investment in quality systems and documentation. ICH Q3A/Q3B compliance for impurity standards requires rigorous analytical method development and validation.
Regioselectivity challenges: The synthetic challenge of achieving regioselective N2-methylation over the competing N1-methylation pathway requires specialized expertise and careful process control, creating barriers to entry for new suppliers.
Limited scale: As a specialized pharmaceutical intermediate, the market for 2,3-dimethyl-2H-indazol-6-amine is smaller than that of commodity chemicals.
Competition from alternative building blocks: The market faces competition from other kinase inhibitor building blocks and alternative synthetic routes to Pazopanib intermediates.
Storage requirements: The compound requires storage at 2–8°C under inert atmosphere, which may increase handling and logistics costs.

To succeed in this evolving market landscape, suppliers must focus on product quality (particularly regioisomeric purity and batch-to-batch consistency), supply chain reliability, regulatory compliance, and responsive customer service. Companies that can offer high-purity products, flexible packaging options, and technical support for pharmaceutical, oncology drug development, and medicinal chemistry applications will be well-positioned to capture growing demand.

Shanghai XinChem Co., Ltd. (XinChem)

As a world-leading supplier of organic chemicals and pharmaceutical intermediates, Shanghai XinChem Co., Ltd. (XinChem) is dedicated to meeting the innovative needs of the pharmaceutical, oncology, and biotechnology industries. Leveraging extensive experience and advanced manufacturing capabilities, XinChem provides high-quality 2,3-Dimethyl-2H-indazol-6-amine (CAS# 444731-72-0) to customers worldwide. As a trusted manufacturer and supplier based in China, XinChem combines competitive pricing, reliable supply, and exceptional service to establish itself as a preferred partner for pharmaceutical companies, oncology drug manufacturers, and research institutions seeking this versatile regioselective 2H-indazole building block.

1. Technical Advantages

Advanced Synthesis and Purification Processes
XinChem utilizes state-of-the-art manufacturing facilities and rigorous quality control measures to ensure the purity, consistency, and safety of its 2,3-dimethyl-2H-indazol-6-amine products. The production process incorporates established synthetic routes—including the regioselective methylation of 3-methyl-6-nitro-1H-indazole using trimethyloxonium tetrafluoroborate (Meerwein’s salt) or trimethyl orthoformate with catalytic control, followed by Pd/C-catalyzed hydrogenation to reduce the nitro group to the primary amine. Critical control of reaction temperature (maintained at 60°C) and purification by crystallization are employed to remove the undesired N1-isomer. This enables the delivery of products with purity ≥97% and ≥99% available to meet diverse application requirements. Strict process control ensures consistent product quality, minimal impurities, and batch-to-batch reproducibility, providing customers with reliable performance in Pazopanib synthesis, pharmaceutical impurity standards, and kinase inhibitor R&D.

Full-Chain Quality Control
The production process strictly adheres to international quality standards, with comprehensive quality control covering raw material sourcing, in-process monitoring, and finished product testing. Each batch is accompanied by a detailed Certificate of Analysis (COA) documenting physical and chemical properties, purity data (HPLC), and impurity profiles. This commitment to quality ensures that XinChem’s 2,3-dimethyl-2H-indazol-6-amine meets the stringent requirements of pharmaceutical R&D, Pazopanib manufacturing, and pharmaceutical quality control applications.

2. Product Advantages

High Purity and Consistent Quality
XinChem offers 2,3-dimethyl-2H-indazol-6-amine with purity ≥97% (HPLC) and ≥99% available, ensuring optimal performance in Pazopanib synthesis, pharmaceutical impurity standards, and kinase inhibitor R&D. The product’s high purity minimizes the risk of unwanted side reactions and impurities, making it suitable for demanding applications in oncology drug development and pharmaceutical quality control. The compound is available as a solid crystalline powder with dark brown to very dark orange color, consistent with reference specifications.

Comprehensive Specifications
Key specifications include:

Molecular Formula: C₉H₁₁N₃
Molecular Weight: 161.20 g/mol
CAS Number: 444731-72-0
Synonyms: 6-Amino-2,3-dimethyl-2H-indazole; 2,3-Dimethyl-6-amino-2H-indazole; 2,3-Dimethylindazol-6-amine; Pazopanib Related Compound 5
MDL Number: MFCD09258896
Appearance: Solid; dark brown to very dark orange
Purity: ≥97% (HPLC) / ≥99% available
Boiling Point: 366.9±22.0°C at 760 mmHg
Density: 1.23±0.1 g/cm³
pKa: 4.20±0.30
Solubility: DMSO (slightly), methanol (slightly)
Storage: 2–8°C, protect from light and moisture, inert atmosphere
GHS Classification: Warning; H302
HS Code: 2922390090

Flexible Packaging Solutions
XinChem provides a range of packaging options to accommodate diverse customer needs, from laboratory-scale quantities (250 mg, 1 g, 5 g, 10 g) to industrial-scale packaging (25 g, 100 g, 500 g, 1 kg, 5 kg, 25 kg) and bulk shipments (200 kg drums). Customized packaging solutions are available upon request, ensuring safe handling, storage, and transportation with appropriate protection from light and moisture.

3. Application Fields

As a versatile regioselective 2H-indazole building block, 2,3-Dimethyl-2H-indazol-6-amine (CAS# 444731-72-0) exhibits wide application value across multiple industries:

Pharmaceutical Synthesis and Pazopanib Manufacturing:

Essential intermediate for Pazopanib hydrochloride (Votrient®), a multi-target TKI for renal cell carcinoma and soft tissue sarcoma
Key building block for N-(2-chloropyrimidin-4-yl)-2,3-dimethyl-2H-indazol-6-amine (CAS 444731-74-2), a critical Pazopanib precursor
Precursor for the synthesis of Pazopanib-related compounds and analogs
Intermediate for 2H-indazole-based VEGFR/PDGFR/c-Kit inhibitors

Pharmaceutical Impurity Reference Standards:

Pazopanib Impurity 7 reference standard for ICH Q3A/Q3B compliance
Pazopanib Related Compound 5 for pharmaceutical quality control
Analytical standard for HPLC and LC-MS method development and validation
Quality control material for oncology drug manufacturing

Kinase Inhibitor R&D and Medicinal Chemistry:

Building block for Pazopanib-inspired kinase inhibitor libraries
Scaffold for angiokinase inhibitor development targeting VEGFR, PDGFR, and c-Kit
Precursor for N,2,3-trimethyl-2H-indazol-6-amine (CAS 1376676-65-1)
Tool for studying Type II kinase inhibitor binding modes (DFG-out conformation)

4. Service Support

Technical Expertise and Customized Solutions
XinChem’s team of experienced chemists and pharmaceutical scientists provides full technical support throughout the customer journey—from product selection and specification development to application guidance and troubleshooting. Whether customers require optimization of Pazopanib synthesis protocols, guidance on regioselective methylation strategies, or assistance with regulatory documentation, XinChem’s technical experts are ready to help. Custom synthesis and contract manufacturing with flexible scaling from R&D to commercial quantities are available upon request.

Global Logistics and Reliable Supply
With established supply chains serving markets across Europe, North America, Asia-Pacific, and beyond, XinChem ensures timely delivery and consistent product availability. The company’s logistics team manages all aspects of international shipping, including customs clearance and documentation, with appropriate temperature control (2–8°C) and moisture protection for product stability.

Regulatory Support
XinChem provides comprehensive documentation to support regulatory compliance, including Safety Data Sheets (SDS), Certificates of Analysis (COA), and other required certificates. The company stays current with evolving regulatory requirements in major markets, including REACH (active registration), ICH Q3A/Q3B, FDA, and other regional regulations, helping customers navigate the complexities of global pharmaceutical trade.

5. Reasons to Choose XinChem

Professionalism: Extensive experience and deep expertise in heterocyclic building block synthesis and supply.
Quality: Rigorous quality control, high purity (≥97% to ≥99%), and adherence to international standards.
Reliability: Stable supply, competitive pricing, and timely delivery.
Flexibility: Customized solutions to meet diverse customer needs, including custom synthesis and packaging.
Service: Responsive technical support and comprehensive documentation.

Website: www.xinchem.com

Email: sales1@xinchem.com

WhatsApp: +86 18049800532

Post time: Sep-24-2026

The Regioselective 2H-Indazole Building Block and Essential Intermediate for Pazopanib and Angiokinase Inhibitor Therapeutics: 2,3-Dimethyl-2H-indazol-6-amine (CAS# 444731-72-0)